Novavax (NVAX) reports earnings tomorrow: what to expect

What happened

Novavax was scheduled to report earnings Thursday before market hours. Last quarter, it reported $56.7 million in revenue, down 76.3% year on year, while beating analysts’ revenue and earnings-per-share estimates. For the upcoming quarter, the market expected revenue to fall 36.4% year on year.

Confirmed

Global impact / market context

The expected revenue decline points to continued pressure on Novavax’s sales, which can limit cash coming into the business and its ability to fund operations. The earnings report could show whether revenue performs better or worse than expected, potentially changing investors’ view of the company’s outlook.

Analyst inference

Analysts had generally reaffirmed their estimates during the 30 days before the report, suggesting expectations were stable. The article says Novavax rarely misses revenue estimates. Biogen and Amgen reported revenue growth in their latest quarters, but their results do not establish Novavax’s performance.

Confirmed

What to watch

1. Compare Novavax’s reported revenue with the expected 36.4% year-on-year decline; a smaller fall would indicate sales held up better than the market forecast. Analyst inference
2. Check whether Novavax beats or misses analysts’ revenue and earnings-per-share estimates, since those results can shift expectations about near-term sales and operating performance. Analyst inference
3. Look for any company explanation of the revenue trend or outlook in the earnings report; the supplied article does not provide Novavax’s reported results or guidance. Analyst inference

Evidence

• stockstory.org